Agenus launches SaponiQx subsidiary

By The Science Advisory Board staff writers

September 10, 2021 -- Agenus is launching a new subsidiary dedicated to novel adjuvant discovery and vaccine design, the company announced.

The subsidiary, SaponiQx, is building a platform that aims to deliver sustainable manufacturing approaches and a secure supply of known adjuvants. In addition, the platform is designed to discover novel adjuvants and develop vaccines that use optimized antigen-adjuvant pairings, Agenus said.

The subsidiary is collaborating with Ginkgo Bioworks and using Ginkgo's metabolic engineering for novel adjuvant discovery.

Copyright © 2021

BioTech Pharma Summit
September 27-28
Porto Portugal
Infectious Diseases (ID) Week 2021
September 29 - October 3
San Diego, California United States
Imaging Mass Spectrometry Society (IMSS) 3 in 2021
October 3-6
Colorado Springs, Colorado United States
Cell & Gene Meeting on the Mesa
October 10-14
Carlsbad, California United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter